The global allergic conjunctivitis treatment market size was estimated to be worth USD 2.0 billion in 2021. The market is expected to rise at a growth rate of 6.2% in the forecast period of 2023-2031. By 2030, the market value is anticipated to be worth USD 3.4 billion. The increasing incidences of ocular injuries and growing R&D activities are driving the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Allergic conjunctivitis is an ocular allergy caused by foreign agents like household dust, animal dander, pollen, chemical scents, or mould spores. The inflammation in the eye is caused due to an allergic reaction to allergens. Depending on the duration, allergic conjunctivitis can be of two types: Acute and Chronic.
Acute allergic conjunctivitis is the most common type and stays for a short term, while chronic one stays for a year or longer, and symptoms come and go as per the environmental conditions.
The human body produces a potent chemical, histamine in response to any foreign agents. As the allergens enter the eye, the body releases histamine as a defence mechanism. This leads to irritation, itching, and inflammation in the eye.
The diagnosis of the condition is done through eye monitoring and ophthalmological tests. An allergy skin test is also used to confirm the incidence of allergic conjunctivitis. The antibodies produced by the body are detected through blood tests. This is also an effective diagnostic procedure for allergic conjunctivitis disease.
There are no specific treatment guidelines for the management of allergic conjunctivitis. Home care remedies include washing the eyes and applying a cool compress to the eyes. In case of a severe problem, medications are used for the treatment. The anti-histaminic drugs, anti-inflammatory eye drugs, or eye drops can be used to alleviate allergic symptoms.
According to this study, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis
Market Breakup by Drug Class
Market Breakup by Disease Type
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increase in the incidence of ocular allergies is the primary reason for market development. Due to rapid urbanisation and rising allergens, the susceptibility to allergic conjunctivitis increases. This is driving the growth of the market.
Increasing awareness has led to more adoption of medications and drugs for the management of ophthalmological problems. This has facilitated the demand of the treatment market. Easy availability and accessibility have also been attributed to the increased allergic conjunctivitis treatment market growth.
Increased investments in research and developmental activities, a major influx of generic drugs and a rising population, are some of the additional factors contributing to the growth of the market.
Among the drug classes, antihistamines are anticipated to have the largest share in the allergic conjunctivitis treatment market. Antihistamines and mast cell stabilizers are the cornerstone therapy for the management of allergic problems. Novel product launches in this drug class are also expected to boost the growth of the market during the forecast period.
North America is expected to have the greatest share in the market owing to the increased prevalence, greater awareness, and presence of significant key players in that region.
Following North America, Europe is projected to dominate among all the regional markets. The factors contributing to this share are more usage of sophisticated medications and the rising patient population.
The Asia Pacific region is anticipated to be the fastest-growing region in the allergic conjunctivitis treatment market. This is attributed to the raising awareness and significant improvements in the healthcare sector.
Allergic Conjunctivitis is caused due to the overreaction of the immune system of the body towards an allergic response. There are different therapeutic options for the management of allergic conjunctivitis depending on the type and severity of the allergy. A major part of therapeutic interventions is also used as a precautionary measure against environmental allergies.
Antihistamines, mast cell stabilisers, and corticosteroids are used to treat allergic symptoms. Drug treatment is the first line of treatment for allergic conjunctivitis. Antihistamines block the secretion of histamines, which are released due to the reaction of an immune system. Oral histamines and eye drops are the two forms of administration. Examples of antihistamines are cetirizine, loratadine, ketotifen and azelastine.
Mast cell stabilisers stabilise the mast cells and take a bit longer time to show their effect. These medications are administered in the form of eye drops. The most used mast cell stabilisers are nedocromil and lodoxamide.
Corticosteroids are only used in case of severe symptoms. These medications reduce inflammation and help in lowering the body’s immune response. These drugs should be used in short term due to their side effects.
There are other additional treatments used for alleviating symptoms. Artificial tears are the oral eye drops used to dilute the allergen and help in its elimination. Cold compresses are applied to provide a soothing effect to the eye and provides a relaxing effect.
The currently available medications and therapeutic interventions are optimal for the management of allergic conjunctivitis. However, preclinical, and clinical studies are under process to discover novel medications that are more effective and have lesser side effects.
Topical steroids are commonly used for managing allergic symptoms. Clinical trials are being done for ester-based steroids, which are anticipated to have fewer adverse effects and better therapeutic potential. Mapracorat is presently under clinical studies. It reduces the uptake of eosinophils and helps in reducing inflammation.
Cyclosporine A is currently under clinical trials for assessing its efficacy and other side effects. The discovery of cyclosporine will reduce the reliance on topical steroids. Clinical studies are under process for determining the optimal cyclosporin concentration for distinct types of allergic conjunctivitis. Researchers are also conducting pre-clinical studies to check drug safety in the paediatric population.
Japan is conducting clinical trials for the ophthalmic application of calcineurin inhibitors. Tacrolimus eye drops are under research and have shown promising results in the early phases of clinical testing. This medication is under advanced testing for further evaluation.
The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of allergic conjunctivitis. The novel product launches will facilitate the expansion of the market.
The report gives an in-depth analysis of the key players involved in the allergic conjunctivitis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis||
|Breakup by Drug Class||
|Breakup by Disease Type||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Allergic Conjunctivitis Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
188.8.131.52 Patent Status and Expiry
184.108.40.206 Timelines from Drug Development to Commercial Launch
220.127.116.11 New Drug Application
18.104.22.168.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
22.214.171.124 US FDA
126.96.36.199 EU EMA
188.8.131.52 INDIA CDSCO
184.108.40.206 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Allergic Conjunctivitis Treatment Market
8.1 Global Allergic Conjunctivitis Treatment Market Overview
8.2 Global Allergic Conjunctivitis Treatment Market Analysis
8.2.1 Market Overview
220.127.116.11 Global Allergic Conjunctivitis Treatment Market Historical Value (2016-2022)
18.104.22.168 Global Allergic Conjunctivitis Treatment Market Forecast Value (2023-2031)
8.3 Global Allergic Conjunctivitis Treatment Market by Diagnosis
8.3.1 Market Overview
22.214.171.124 Allergy Skin Test
126.96.36.199 Blood Test
8.4 Global Allergic Conjunctivitis Treatment Market by Drug Class
8.4.1 Market Overview
188.8.131.52 Antihistamines and Mast Cell Stabilisers
8.5 Global Allergic Conjunctivitis Treatment Market by Disease Type
8.5.1 Market Overview
184.108.40.206 Seasonal Allergic Conjunctivitis
220.127.116.11 Contact Conjunctivitis
18.104.22.168 Giant Papillary Conjunctivitis
22.214.171.124 Perennial Conjunctivitis
126.96.36.199 Vernal Keratoconjunctivitis
188.8.131.52 Atopic Keratoconjunctivitis
8.6 Global Allergic Conjunctivitis Treatment Market by Treatment Channel
8.6.1 Market Overview
8.7 Global Allergic Conjunctivitis Treatment Market by Region
8.7.1 Market Overview
184.108.40.206 North America
220.127.116.11 Asia Pacific
18.104.22.168 Middle East and Africa
22.214.171.124 Latin America
9 North America Allergic Conjunctivitis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Allergic Conjunctivitis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Allergic Conjunctivitis Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Allergic Conjunctivitis Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Allergic Conjunctivitis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Allergic Conjunctivitis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sun Pharmaceutical Industries Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Bausch & Lomb
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 AbbVie Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Ocular Therapeutix, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Alexion Pharmaceuticals Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Santen Pharmaceutical Co., Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Dr. Reddy’s Laboratories Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Alembic Pharmaceuticals Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Grevis Pharmaceuticals Pvt. Ltd.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
16 Global Allergic Conjunctivitis Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
Allergic conjunctivitis is an ocular allergy caused by foreign agents like household dust, animal dander, pollen, chemical scents, or mould spores.
Corticosteroids, antihistamines, and mast cell stabilisers are the primary drugs used to manage allergic conjunctivitis.
Based on the drug class, the market is segmented into antihistamines and mast cell stabilizers, corticosteroids, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa.
The two types of allergic conjunctivitis are acute and chronic.
The treatment channels in the market are public and private.
Increasing incidence of ocular allergies, raising awareness and growing investments in the research and development sector are the driving factors in the market.
North America is anticipated to hold a significant share in the market during the forecast period.
The key companies involved in the market are Sun Pharmaceutical Industries Limited, Novartis AG, Bausch & Lomb, AbbVie Inc., Ocular Therapeutix, Inc., Alexion Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Ltd., and Grevis Pharmaceuticals Pvt. Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.